[HTML] thieme-connect.com

[HTML][HTML] The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese patients without diabetes: a systematic review and meta-analysis

X Guo, Z Zhou, X Lyu, H Xu, H Zhu… - Hormone and …, 2022 - thieme-connect.com
Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …
被引用次数：42 相关文章

The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.

X Guo, Z Zhou, X Lyu, H Xu, H Zhu, H Pan… - Hormone and …, 2022 - europepmc.org
Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis

X Guo, Z Zhou, X Lyu, H Xu, H Zhu… - Hormone and …, 2022 - thieme-connect.com
Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis

X Guo, Z Zhou, X Lyu, H Xu, H Zhu… - Hormone and …, 2022 - pubmed.ncbi.nlm.nih.gov
Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …